We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.63%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$25.6M
Cap. Flow
-$43.5M
Cap. Flow %
-39.89%
Top 10 Hldgs %
43.42%
Holding
74
New
7
Increased
2
Reduced
48
Closed
7

Top Buys

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$2.22M
2
RXDX
Ignyta, Inc.
RXDX
+$1.38M
3
CKPT
Checkpoint Therapeutics
CKPT
+$1.16M
4
KPTI icon
Karyopharm Therapeutics
KPTI
+$987K
5
LOXO
Loxo Oncology, Inc
LOXO
+$765K

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.61M
2
IBB icon
iShares Biotechnology ETF
IBB
+$3.69M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.62M
4
ALKS icon
Alkermes
ALKS
+$2.41M
5
INCY icon
Incyte
INCY
+$2.22M

Sector Composition

Rank Sector Weight
1 Healthcare 65.96%
2 Miscellaneous 33.66%
3 Real Estate 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
26
Illumina
ILMN
$33.6B
$1.72M 1.58%
10,193
-9,783
-49% -$1.69M
AMGN icon
27
Amgen
AMGN
$203B
$1.69M 1.55%
9,821
-9,580
-49% -$1.56M
BIIB icon
28
Biogen
BIIB
$31.9B
$1.57M 1.44%
5,777
-5,627
-49% -$1.49M
BMRN icon
29
BioMarin Pharmaceuticals
BMRN
$12.5B
$1.52M 1.39%
16,762
-16,149
-49% -$1.47M
AGIO icon
30
Agios Pharmaceuticals
AGIO
$1.96B
$1.52M 1.39%
29,482
-27,928
-49% -$1.43M
CLVS
31
DELISTED
Clovis Oncology, Inc.
CLVS
$1.4M 1.29%
15,000
-15,000
-50% -$918K
LLY icon
32
CALL
Eli Lilly
LLY
$1.01T
$1.24M 1.13%
15,000
– –
PCRX icon
33
Pacira BioSciences
PCRX
$960M
$1.19M 1.09%
25,000
-25,000
-50% -$1.16M
ALXN
34
DELISTED
Alexion Pharmaceuticals
ALXN
$1.16M 1.06%
9,526
-9,175
-49% -$1.07M
LOXO
35
DELISTED
Loxo Oncology, Inc
LOXO
$1.11M 1.01%
+13,800
New +$765K
LABU icon
36
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$469M
$1.01M 0.92%
800
+364
+83% +$367K
PRTK
37
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$964K 0.88%
40,000
-40,000
-50% -$884K
KPTI icon
38
Karyopharm Therapeutics
KPTI
$34.9M
$905K 0.83%
+6,667
New +$987K
AXSM icon
39
Axsome Therapeutics
AXSM
$10.7B
$734K 0.67%
133,500
-133,500
-50% -$559K
GILD icon
40
CALL
Gilead Sciences
GILD
$181B
$706K 0.65%
10,000
– –
TSRO
41
DELISTED
TESARO, Inc.
TSRO
$699K 0.64%
5,000
-5,000
-50% -$724K
KITE
42
DELISTED
Kite Pharma, Inc.
KITE
$613K 0.56%
5,915
-16
-0.3% -$1.31K
JUNO
43
DELISTED
Juno Therapeutics, Inc.
JUNO
$537K 0.49%
17,970
-60
-0.3% -$1.48K
MDCO
44
DELISTED
Medicines Co
MDCO
$532K 0.49%
14,000
-14,000
-50% -$624K
CKPT
45
DELISTED
Checkpoint Therapeutics
CKPT
$530K 0.49%
+11,776
New +$1.16M
MYGN icon
46
Myriad Genetics
MYGN
$371M
$527K 0.48%
20,414
-70
-0.3% -$1.49K
ADMS
47
DELISTED
Adamas Pharmaceuticals
ADMS
$525K 0.48%
30,000
-30,000
-50% -$496K
PGEN icon
48
Precigen
PGEN
$2.51B
$442K 0.4%
18,345
-66
-0.4% -$1.45K
SNR
49
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$421K 0.39%
41,850
-41,850
-50% -$420K
SIOX
50
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$404K 0.37%
2,178
– –
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2017 Portfolio in Review

As of Q2 2017, Opus Point Partners Management held 74 positions worth $109M, down 19% from $135M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opus Point Partners Management withdrew a net $43.5M in Q2 2017, closing 7 positions and reducing 48 holdings. Its most notable exit was Portola Pharmaceuticals, Inc., an estimated $980K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 77% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in Ignyta, Inc. worth $1.76M.

  • Opus Point Partners Management's largest Q2 2017 buy was Ignyta, Inc.: 170,500 shares worth $1.76M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q2 2017, an estimated $2.22M increase.
  • Opus Point Partners Management's biggest Q2 2017 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.61M.
  • Opus Point Partners Management fully exited Portola Pharmaceuticals, Inc. in Q2 2017, selling an estimated $980K.
  • Opus Point Partners Management's ten largest holdings make up 43% of its $109M portfolio in Q2 2017.
  • Opus Point Partners Management opened 7 new positions and closed 7 in Q2 2017.
  • Opus Point Partners Management's portfolio value fell 19% quarter-over-quarter to $109M.

Based on Opus Point Partners Management's 13F filing for Q2 2017, filed 14 Aug 2017.